Plexxikon

Berkeley, United States Founded: 2000 • Age: 26 yrs Acquired By Daiichi Sankyo
Develops small molecule pharmaceuticals for oncology, CNS and autoimmune diseases
Request Access

About Plexxikon

Plexxikon is a company based in Berkeley (United States) founded in 2000 was acquired by Daiichi Sankyo in February 2011.. Plexxikon has raised $72.86 million across 2 funding rounds from investors including Daiichi Sankyo, Gimv and Pappas Capital. Plexxikon offers products and services including Zelboraf and Turalio. Plexxikon operates in a competitive market with competitors including Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.

  • Headquarter Berkeley, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Plexxikon Inc.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $72.86 M (USD)

    in 2 rounds

  • Latest Funding Round
    $46 M (USD), Series B

    May 26, 2004

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Daiichi Sankyo

    (Feb 28, 2011)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Plexxikon

Plexxikon offers a comprehensive portfolio of products and services, including Zelboraf and Turalio. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

A drug invented for personalized medicine treatments.

Another drug developed for personalized medicines.

People of Plexxikon
Headcount 50-200
Employee Profiles 1
Board Members and Advisors 3
Employee Profiles
People
Chao Zhang
Senior Vice President, Research

Unlock access to complete

Funding Insights of Plexxikon

Plexxikon has successfully raised a total of $72.86M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $46 million completed in May 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series B — $46.0M
  • First Round

    (25 Apr 2002)

  • Investors Count 7
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2004 Amount Series B - Plexxikon Valuation

investors

Apr, 2002 Amount Series A - Plexxikon Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Plexxikon

Plexxikon has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Daiichi Sankyo, Gimv and Pappas Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
VC firm focusing on life science sector
Founded Year Domain Location
VC firm making investment in early stage startups in the US
Founded Year Domain Location
Venture capital firm focused on healthcare companies
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Plexxikon

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Plexxikon

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Plexxikon Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Plexxikon

Plexxikon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Pharmaceutical products are manufactured and marketed worldwide.
domain founded_year HQ Location
Biopharmaceutical research and drug development are conducted globally by AbbVie.
domain founded_year HQ Location
Traditional pharmaceutical medicines are developed for multiple health fields.
domain founded_year HQ Location
Pharmaceuticals and diagnostics kits are developed for various diseases.
domain founded_year HQ Location
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
domain founded_year HQ Location
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Plexxikon

Frequently Asked Questions about Plexxikon

When was Plexxikon founded?

Plexxikon was founded in 2000 and raised its 1st funding round 2 years after it was founded.

Where is Plexxikon located?

Plexxikon is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.

Is Plexxikon a funded company?

Plexxikon is a funded company, having raised a total of $72.86M across 2 funding rounds to date. The company's 1st funding round was a Series A of $26.86M, raised on Apr 25, 2002.

What does Plexxikon do?

Founded in 2000 in Berkeley, United States, Plexxikon operates in the pharmaceutical sector, focusing on small molecule drugs for oncology, central nervous system disorders, and autoimmune conditions. A proprietary Scaffold-Based Drug Discovery Platform is utilized to create selective therapies. ZELBORAF (vemurafenib), discovered in 2005, was co-developed with Roche and approved in over 40 countries, accompanied by a diagnostic tool. The company was acquired by Daiichi Sankyo in 2011.

Who are the top competitors of Plexxikon?

Plexxikon's top competitors include Merck, Roivant Sciences and Amgen.

What products or services does Plexxikon offer?

Plexxikon offers Zelboraf and Turalio.

Who are Plexxikon's investors?

Plexxikon has 8 investors. Key investors include Daiichi Sankyo, Gimv, Pappas Capital, Advanced Technology Ventures, and Alta Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available